Impact of hemolysis on uracilemia in the context of dihydropyrimidine dehydrogenase deficiency testing

Clin Chem Lab Med. 2024 Jan 11;62(6):e129-e131. doi: 10.1515/cclm-2023-1096. Print 2024 May 27.

Authors

Gaspard Loison¹, Hélène Bouges Le Royer², Sabrina Marsili^{1

3}, Aurélie Brice^{1

3}, Julien Vintejoux^{1

3}, Malika Yakoubi^{1

3}, Hélène Sirgue^{1

3}, Etienne Chatelut^{1

3}, Marie-Christine Etienne-Grimaldi², Fabienne Thomas^{1

4

3

5}; on behalf of the GPCO-UNICANCER group

Affiliations

¹ Laboratory of Pharmacology, Oncopole Claudius Regaud, Toulouse, France.
² Laboratory of Oncopharmacology, Centre Antoine Lacassagne, Nice, France.
³ Centre de Recherche en Cancérologie de Toulouse, INSERM U1037, Université Paul Sabatier, Toulouse, France.
⁴ University Paul Sabatier, Toulouse, France.
⁵ Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France.

PMID: 38198224
DOI: 10.1515/cclm-2023-1096

No abstract available

Keywords: DPD deficiency; dihydrouracil; hemolysis; uracil.

Publication types

Letter
Case Reports

MeSH terms

Dihydropyrimidine Dehydrogenase Deficiency* / diagnosis
Dihydrouracil Dehydrogenase (NADP) / genetics
Dihydrouracil Dehydrogenase (NADP) / metabolism
Hemolysis*
Humans

Substances

Dihydrouracil Dehydrogenase (NADP)